{
    "id": 2813,
    "fullName": "MED12 dec exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "MED12 dec exp indicates decreased expression of the MED12 protein and/or mRNA. However, the mechanism causing the decreased expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 9968,
        "geneSymbol": "MED12",
        "terms": [
            "MED12",
            "ARC240",
            "CAGH45",
            "FGS1",
            "HOPA",
            "Kto",
            "MED12S",
            "OHDOX",
            "OKS",
            "OPA1",
            "TNRC11",
            "TRAP230"
        ]
    },
    "variant": "dec exp",
    "createDate": "12/22/2014",
    "updateDate": "08/28/2017",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 1534,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, knock down of MED12 expression in non-small cell lung cancer cell lines resulted in resistance to Xalkori (crizotinib) in culture (PMID: 23178117).",
            "molecularProfile": {
                "id": 2647,
                "profileName": "MED12 dec exp"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 1455,
                    "pubMedId": 23178117,
                    "title": "MED12 controls the response to multiple cancer drugs through regulation of TGF-\u03b2 receptor signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23178117"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1536,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, knock down of MED12 expression in EGFR mutant NSCLC cell lines resulted in resistance to gefitinib or erlotinib (PMID: 23178117).",
            "molecularProfile": {
                "id": 2648,
                "profileName": "EGFR mut MED12 dec exp"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 1455,
                    "pubMedId": 23178117,
                    "title": "MED12 controls the response to multiple cancer drugs through regulation of TGF-\u03b2 receptor signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23178117"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1535,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, knock down of MED12 expression in EGFR mutant NSCLC cell lines resulted in resistance to gefitinib or erlotinib (PMID: 23178117).",
            "molecularProfile": {
                "id": 2648,
                "profileName": "EGFR mut MED12 dec exp"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 1455,
                    "pubMedId": 23178117,
                    "title": "MED12 controls the response to multiple cancer drugs through regulation of TGF-\u03b2 receptor signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23178117"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1537,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, knock down of MED12 expression in BRAF V600E melanoma cell lines resulted in resistance to vemurafenib or selumetinib (PMID: 23178117).",
            "molecularProfile": {
                "id": 2649,
                "profileName": "BRAF V600E MED12 dec exp"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 1455,
                    "pubMedId": 23178117,
                    "title": "MED12 controls the response to multiple cancer drugs through regulation of TGF-\u03b2 receptor signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23178117"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1539,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, knock down of MED12 expression in BRAF V600E or KRAS G12V mutant colorectal cancer cell lines resulted in resistance to AZD6244 (PMID: 23178117).",
            "molecularProfile": {
                "id": 2649,
                "profileName": "BRAF V600E MED12 dec exp"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 1455,
                    "pubMedId": 23178117,
                    "title": "MED12 controls the response to multiple cancer drugs through regulation of TGF-\u03b2 receptor signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23178117"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1538,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, knock down of MED12 expression in BRAF V600E melanoma cell lines resulted in resistance to vemurafenib or selumetinib (PMID: 23178117).",
            "molecularProfile": {
                "id": 2649,
                "profileName": "BRAF V600E MED12 dec exp"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 1455,
                    "pubMedId": 23178117,
                    "title": "MED12 controls the response to multiple cancer drugs through regulation of TGF-\u03b2 receptor signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23178117"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1540,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, knock down of MED12 expression in BRAF V600E or KRAS G12V mutant colorectal cancer cell lines resulted in resistance to AZD6244 (PMID: 23178117).",
            "molecularProfile": {
                "id": 2650,
                "profileName": "KRAS G12V MED12 dec exp"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 1455,
                    "pubMedId": 23178117,
                    "title": "MED12 controls the response to multiple cancer drugs through regulation of TGF-\u03b2 receptor signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23178117"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 2647,
            "profileName": "MED12 dec exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 2648,
            "profileName": "EGFR mut MED12 dec exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 2649,
            "profileName": "BRAF V600E MED12 dec exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 2650,
            "profileName": "KRAS G12V MED12 dec exp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}